News | January 20, 2023
Blue Jet Healthcare gets SEBI nod for IPO
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
Connectivity and harmonisation were both key driving factors behind our decision to choose the CARA Life Sciences Platform to consolidate our processes
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
Point-of-Care solution to facilitate clinicians in quick and effective decision making
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
India's G20 Presidency will focus on three main priorities: Health Emergencies Prevention, Preparedness and Response (One Health & AMR); Access and Availability to Affordable Medical Countermeasures (Vaccines, Therapeutics, and Diagnostics); and Digital Health
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
Subscribe To Our Newsletter & Stay Updated
